BioNTech's BNT113 Combo Vaccine Misses Key Progression-Free Survival Goal, Shares Reflect Mixed Outlook (BNTX)

gurufocus.com · 2026-10-13

On October 13, 2026, BioNTech SE (NASDAQ: BNTX) announced that its new combination vaccine candidate, BNT113, failed to meet a critical objective of improved pr

Read the full story at gurufocus.com →